SBIR Phase II: A Novel Bacteriophage Mutant as a Platform Carrier for Next Generation Vacc — NSF Award to IASO THERAPEUTICS, INC.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the contribution to the field of conjugate vaccines, which have made revolutionary and tremendous contributions to public health. When successfully developed, the proposed platform will be available for use by
| Award title | SBIR Phase II: A Novel Bacteriophage Mutant as a Platform Carrier for Next Generation Vacc |
|---|---|
| Award ID | 2150936 |
| Awardee | IASO THERAPEUTICS, INC. |
| City | EAST LANSING |
| State | MI |
| Amount obligated | $1,366,595 |
| Principal investigator | Herbert Kavunja |
| Program | SBIR Phase II |
| Start date | 03/01/2022 |
| Abstract | The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the contribution to the field of conjugate vaccines, which have made revolutionary and tremendous contributions to public health. When successfully developed, the proposed platform will be available for use by biotechnology and pharmaceutical companies to develop next-generation conjugate vaccines against a wide range of antigens, including cancer and emerging infectious diseases, for im |
| Source | NSF Awards |
$799/mo
Try NSFGrants →